Gene Therapies for Hemophilia. Possibly Curative, Likely Ultraexpensive
September 8th 2022Three gene therapies in late-stage development are designed to supply working copies of genes that people with hemophilia are missing. They may be one-time, curative treatments, but the seven-figure price tags will be an issue.
Read More
Cost Effectiveness Analysis of Biomarkers for Guiding Asthma Treatment in Children
August 2nd 2022Using biomarkers for tailoring asthma treatment can reduce the frequency of asthma exacerbations. Some recent results suggest that eosinophil-guided asthma management is associated with lower annual costs than FeNO-guided management.
Read More
American Academy of Family Physicians Awarded $31 Million for Comparative Asthma Treatment Study
August 1st 2022The Patient-Centered Outcomes Research Institute (PCORI) has approved an award for the American Academy of Family Physicians (AAFP) of $31 million to fund a large comparative study of asthma treatments.
Read More
Dupixent Combined with House Dust Mite SLIT May Help Improve Control in Allergic Asthma
July 15th 2022House dust mites after a common trigger for allergic asthma. Guidelines recommend house dust mite sublingual immunotherapy as add-on therapy for patients with house dust mite-related allergic asthma.
Read More
IL-13 in People with Allergic Asthma May Offer Some Protection Against Severe COVID
June 14th 2022University of North Carolina researchers report that interleukin-13, responsible for inflammation and severe asthma symptoms, may have properties that fend off the SARS-CoV-2 virus that causes COVID-19.
Read More
Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.
Read More
Fourth Shot is Recommended for the Immunocompromised
March 10th 2022Getting boosted is now the rule, not the exception, when it comes to COVID-19 vaccination recommendations. The CDC now recommends that everyone, ages 12 and older, get a dose of an mRNA COVID-19 vaccine, either Pfizer’s or Moderna’s. For people who have gotten the two-shot Pfizer or Moderna series, the booster is their third jab. For those who got the single-dose Johnson & Johnson vaccine, it is the second.
Read More
Bayer Receives FDA Fast-Track Designation for Next-Generation Anticoagulant
February 18th 2022Asundexian is an oral factor XIa inhibitor currently under phase 2 trials for potential secondary thrombosis prevention in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or recent myocardial infarction.
Read More